Skip to search formSkip to main contentSkip to account menu

CpG 7909

Known as: CpG-7909, CpG7909 
A synthetic 24-mer oligonucleotide containing 3 CpG motifs with potential antineoplastic and immunostimulatory activity. CpG 7909 selectively targets… 
National Institutes of Health

Related topics

Related topics

3 relations
Agatolimod Sodium

Narrower (1)

PF 3512676

Broader (1)

ProMune

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
IRAK-M alters the polarity of macrophages to facilitate the survival of Mycobacterium tuberculosis
Intracellular bacterium, Mycobacterium tuberculosis (M. tb), infects specifically macrophages as host cells. IRAK-M, a member of… 
2013
2013
CpG7909 adjuvant enhanced immunogenicity efficacy in mice immunized with ESAT6‐Ag85A fusion protein, but does not confer significant protection against Mycobacterium tuberculosis infection
This study aimed to investigate the ability of CpG7909 adjuvant to enhance immunogenicity and protective efficacy of a subunit… 
2008
2008
Clinical and immunologic responses to a novel in situ lymphoma vaccine maneuver: Preliminary results of a phase II trial of intra-tumoral CpG 7909
3003 Background: Lymphoma vaccines have shown preliminary clinical success, but their development has been slowed by the… 
2007
2007
Activation of Innate Immunity in Healthy Macaca mulatta Macaques by a Single Subcutaneous Dose of GMP CpG 7909: Safety Data and Interferon-Inducible Protein-10 Kinetics for Humans and Macaques
ABSTRACT Following a demonstration that mouse-optimized cytosine-guanosine dinucleotide (CpG) oligodeoxynucleotides stimulated… 
Review
2007
Review
2007
A Phase I Trial of CpG-7909, Rituximab Immunotherapy, and Y90 Zevalin Radioimmunotherapy for Patients (Pts) with Previously Treated CD20+ Non-Hodgkin Lymphoma (NHL).
Background: CpG 7909 is a synthetic 24 mer oligodeoxynucleotide designed to provide optimal activation of immune mechanisms… 
2006
2006
Survivin: preclinical rationale and preliminary clinical results
Background Vaccination with MAGE peptides is followed by tumor regression in 10–20% of metastatic melanoma patients with… 
2005
2005
Combination of a Toll-like receptor 9 (TLR9) agonist, CPG 7909 (CPG) with first line taxane/platinum improves response rate in late stage non-small-cell lung cancer (NSCLC)
2004
2004
TLR9 Agonist Immunomodulator Treatment of Cutaneous T-Cell Lymphoma (CTCL) with CPG7909.
CPG 7909 belongs to a new class of chemically defined CpG immunomodulators that target dendritic cell TLR9 receptors inducing IL… 
2004
2004
Combination of CpG7909 and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL): A phase I, open label dose-escalation study of safety and tolerability.
6594 Background: CpG ODN are a class of chemically synthesized oligodeoxynucleotides that activate B-cells and plasmacytic… 
2003
2003
Technology evaluation: CpG-7909, Coley.
  • S. Paul
  • Current opinion in molecular therapeutics (Print)
  • 2003
  • Corpus ID: 28835501
Coley Pharmaceutical (formerly CpG ImmunoPharmaceuticals) is developing CpG-7909 (ProMune) for use in the potential treatment of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)